Bristol-Myers Squibb submits New Medication Program to the U.S. Food and Drug Administration for entecavir Bristol-Myers Squibb offers announced the submission of a fresh Drug Application to the U cialis online .S. Food and Drug Administration for entecavir, an investigational antiviral agent under advancement for the treatment of chronic Hepatitis B. In europe, the ongoing company also submitted a advertising authorization application for entecavir to the European Medicines Evaluation Agency. Entecavir is an investigational oral antiviral found out at Bristol-Myers Squibb that’s made to selectively inhibit the Hepatitis B virus, blocking all three guidelines in the replication process..

cialis generic

‘Today’s announcement puts the diabetes franchise in the able hands of AstraZeneca and we can move to a far more simplified operating model in keeping with our pipeline and portfolio.’ Bristol-Myers Squibb and AstraZeneca entered into an alliance contract in January 2007 to enable the companies to jointly research, develop and commercialize select investigational medications for type 2 diabetes. The alliance provides since been expanded to collaborate on additional diabetes products. Bristol-Myers Squibb will sell its global diabetes business that was part of its collaboration with AstraZeneca, which include Onglyza , Kombiglyze XR/Komboglyze , dapagliflozin , Byetta , Bydureon , Symlin and metreleptin.